Tapentadol half-life
Immediate-release tapentadol labeling reports a terminal half-life near four hours; the profile now uses that direct value.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. This is a mathematical visualization, not a personal concentration estimate.
Tapentadol: evidence and interpretation notes
Parent drug, metabolites, and formulation
Immediate-release tapentadol labeling reports a terminal half-life near four hours; the profile now uses that direct value. Extended-release behavior and clinical effect are kept out of the normalized parent-drug model.
The plotted input is 4 hours for Immediate-release parent tapentadol. It is a normalized comparison line, not a reconstruction of a measured blood concentration or a forecast of effects.
Tapentadol is an opioid analgesic with immediate-release and extended-release product contexts, so formulation should be kept separate from the simple curve.
The 5 hour value is the calculator input for parent-drug decline. It does not model analgesic response, norepinephrine reuptake effects, or extended-release exposure.
The entry cites direct labels for immediate-release and extended-release tapentadol plus the compound record.
This page is not a prescribing, conversion, or opioid safety resource.
For Tapentadol, parent-drug decline should be read separately from analgesia, respiratory risk, metabolites, and formulation. Opioid risk is not proportional to the percentage remaining in this simplified chart.
What each source contributes
- DailyMed: Tapentadol hydrochloride tablet. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
- DailyMed: Tapentadol extended-release tablet. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
- PubChem: Tapentadol. This identity record confirms names and compound identity and does not supply a human half-life.
For Tapentadol, the numerical model is tied most closely to DailyMed: Tapentadol hydrochloride tablet. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.
Why there is no range on the chart
This profile plots 4 hours for Immediate-release parent tapentadol without adding an unsourced high-low band. A single supported center is more honest than manufacturing a range from unrelated routes, populations, or formulations.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 4 h as a representative input for Immediate-release parent tapentadol. In the simplified model, about 1.6% remains after 24 hours and about 3% remains after five half-lives, or roughly 20 h.
This sits in the same-day range. The chart is useful for seeing the bend of the curve across a day or two, but it should not be treated as a personal clock. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
opioid context
Opioid pharmacokinetics can differ between parent compounds and metabolites, and timing can vary by route, formulation, and individual clearance.
- Half-life is not a measure of respiratory risk or functional impairment.
- Active metabolites can matter even when the parent compound declines.
- Extended-release products require separate source context.
ComparisonTimeline checkpoints and nearby profiles
Tapentadol timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 6 h | 35.4% | Meaningful modeled decline, not near-zero |
| 12 h | 12.5% | Long-tail portion of the model |
| 24 h | 1.56% | Low modeled remainder, not a clearance guarantee |
| 2.0 days | 0.02% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Tapentadol within the opioid group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Hydrocodone (4 h)
- Tramadol (6 h)
- Fentanyl (3.6 h)
- Oxymorphone (8 h)
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 4 h |
|---|---|
| Modeled analyte or phase | Immediate-release parent tapentadol |
| Curve type | Normalized, first-order decline |
Selection note: Immediate-release tapentadol labeling reports a terminal half-life near four hours; the profile now uses that direct value. Extended-release behavior and clinical effect are kept out of the normalized parent-drug model.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: Tapentadol hydrochloride tablet.Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
- Official labeling DailyMed label: Tapentadol extended-release tablet.Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
- Identity record PubChem Compound Summary: Tapentadol.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the opioid group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.